The characteristics of determination of BRCA1 and BRCA2 mutations in serous ovarian cancer

The characteristics of determination of BRCA1 and BRCA2 mutations in serous ovarian cancer

Mutations of the BRCA1/BRCA2 genes occur in 15-20% cases of ovarian cancer (OC) and are associated with increased sensitivity to platinum drugs and new target drugs that inhibit proteins of poly(ADP-ribose) polymerase family. The discovery of new therapeutic options in the treatment of patients with...

Full description

Bibliographic Details
Main Author:	I A Demidova
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2017-01-01
Series:	Современная онкология
Subjects:	ovarian cancer brca1/brca2 mutations parp inhibitors next-generation sequencing
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/27116/pdf

Similar Items

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer
by: Arianna Nicolussi, et al.
Published: (2019-04-01)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
by: Alena Savanevich, et al.
Published: (2021-01-01)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
by: Tarinee Manchana, et al.
Published: (2020-08-01)

Hereditary ovarian cancer
by: I A Demidova
Published: (2015-09-01)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
by: Sayeh Saravi, et al.
Published: (2021-09-01)

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
by: Ashour M, et al.
Published: (2019-07-01)

BRCA 1/2-mutation related and sporadic breast and ovarian cancers: More alike than different
by: Melissa A. Burgess, et al.
Published: (2014-02-01)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
by: Kyung Jin Eoh, et al.
Published: (2020-03-01)

Tailoring Ovarian Cancer Treatment: Implications of <i>BRCA1/2</i> Mutations
by: Ainhoa Madariaga, et al.
Published: (2019-03-01)

Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
by: Hongyu Deng, et al.
Published: (2019-06-01)

Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements
by: Gulisa Turashvili, et al.
Published: (2020-11-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
by: Jordi Remon, MD, et al.
Published: (2020-09-01)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
by: Tomasz Kluz, et al.
Published: (2018-02-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
by: Anastasia Navitski, et al.
Published: (2021-11-01)

BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population
by: Florencia C. Cardoso, et al.
Published: (2018-08-01)

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review
by: Tao M, et al.
Published: (2020-12-01)

BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography
by: Janelle N. Sobecki, et al.
Published: (2021-02-01)

Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
by: Gabriel S. Macedo, et al.
Published: (2019-04-01)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
by: Robert L. Hollis, et al.
Published: (2018-01-01)

BRCA1, BRCA2 mutations — future of predictive oncology: a review of literature
by: V. N. Dmitriev, et al.
Published: (2014-07-01)

BRCA1 and BRCA2 and Inherited Predisposition to Breast and Ovarian Cancers
by: Patricia N. Tonin
Published: (2002-12-01)

Cytotoxic and targeted therapy for BRCA1/2-driven cancers
by: Evgeny N. Imyanitov
Published: (2021-08-01)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
by: Ewa Przybytkowski, et al.
Published: (2020-03-01)

Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia
by: Dorra Ben Ayed-Guerfali, et al.
Published: (2021-03-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer
by: Tingyan Shi, et al.
Published: (2018-07-01)

The occurrence of ovarian cancer in the population of urban and rural women, BRCA1 and BRCA2 genes mutation testing and the general rules on the patient’s consent to treatment
by: Połocka-Molińska Maria, et al.
Published: (2021-06-01)

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy
by: Caterina Fumagalli, et al.
Published: (2019-10-01)

Feasibility of <i>BRCA1/2</i> Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series
by: Rossella Bruno, et al.
Published: (2021-06-01)

Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil
by: Deborah Porto Cotrim, et al.
Published: (2019-01-01)

Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review
by: Halpern N, et al.
Published: (2020-11-01)

Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing
by: Hyunseok P. Kang, et al.
Published: (2016-06-01)

Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil
by: V.F. Esteves, et al.
Published: (2009-05-01)

Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review
by: Lisa Krassuski, et al.
Published: (2019-08-01)

Emerging treatment options for ovarian cancer: focus on rucaparib
by: Mariappan L, et al.
Published: (2017-12-01)

Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1
by: Tahira Baloch, et al.
Published: (2019-01-01)